Drug Profile
Insulin biosimilar - Harvest Moon Pharmaceuticals
Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Harvest Moon Pharmaceuticals
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 24 Feb 2016 No development reported - Clinical-Phase-Unknown for Diabetes mellitus in European Union (SC)
- 24 Feb 2016 No development reported - Phase-III for Diabetes mellitus in USA (SC)
- 24 Feb 2016 No development reported - Registered for Diabetes mellitus in Brazil (SC)